Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O60828
UPID:
PQBP1_HUMAN
Alternative names:
38 kDa nuclear protein containing a WW domain; Polyglutamine tract-binding protein 1
Alternative UPACC:
O60828; C9JQA1; Q4VY25; Q4VY26; Q4VY27; Q4VY29; Q4VY30; Q4VY34; Q4VY35; Q4VY36; Q4VY37; Q4VY38; Q9GZP2; Q9GZU4; Q9GZZ4
Background:
Polyglutamine-binding protein 1, also known as a 38 kDa nuclear protein containing a WW domain, plays a pivotal role in various cellular processes. This intrinsically disordered protein acts as a scaffold in pre-mRNA splicing, transcription regulation, innate immunity, and neuron development. It interacts with splicing-related factors, regulates alternative splicing of target pre-mRNA species, and is involved in the assembly of cytoplasmic stress granule.
Therapeutic significance:
Linked to Renpenning syndrome 1, a condition marked by intellectual disability and physical anomalies, Polyglutamine-binding protein 1's understanding could pave the way for innovative treatments. Its involvement in neuron development and response to cellular stress highlights its potential in therapeutic strategies targeting neurodevelopmental disorders and stress-related conditions.